Oxidative stress, mitochondrial damage and neurodegenerative diseases

Neural Regeneration Research

Volumn 8, Issue 21, 2013, Pages 2003-2014

  Guo, Chun Yan ^a   Sun, Li ^a   Chen, Xue Ping ^b   Zhang, Dan Shen ^c  

^a HEBEI NORTH UNIVERSITY   (China)

^b UNIVERSITY OF MANITOBA   (Canada)

^c HEBEI UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Grants supported paper; Mitochondrial damage; Neural regeneration; Neurodegenerative diseases; Neuroregeneration; Oxidative stress; Parkinson's disease; Reactive oxygen species; Respiratory chain

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; BETA SECRETASE; CALBINDIN; CALCIUM ION; CATALASE; CYTOCHROME C OXIDASE; DNA DIRECTED DNA POLYMERASE GAMMA; FLAVINE ADENINE NUCLEOTIDE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; HYDROGEN PEROXIDE; LEUCINE RICH REPEAT KINASE 2; MITOCHONDRIAL DNA; MITOCHONDRIAL TRANSCRIPTION FACTOR A; OXOGLUTARATE DEHYDROGENASE; PARKIN; PARVALBUMIN; PEROXYNITRITE; PYRUVATE DEHYDROGENASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; SERINE PROTEINASE OMI; SUCCINATE DEHYDROGENASE; SUPEROXIDE DISMUTASE; UBIQUINOL CYTOCHROME C REDUCTASE; UBIQUINONE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; ARTICLE; CALCIUM HOMEOSTASIS; CELL DAMAGE; CELL MEMBRANE PERMEABILITY; DEGENERATIVE DISEASE; DNA DAMAGE; DOWN SYNDROME; ELECTRON MICROSCOPY; EXCITOTOXICITY; HUMAN; HUNTINGTON CHOREA; MITOCHONDRIAL MEMBRANE; NITROSYLATION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN PHOSPHORYLATION; RESPIRATORY CHAIN;

EID: 84889860617     PISSN: 16735374     EISSN: 18767958     Source Type: Journal    
DOI: 10.3969/j.issn.1673-5374.2013.21.009     Document Type: Article

References (126)

1. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443 (7113):787-795.
2. Martin LJ. Mitochondrial and cell death mechanisms in neurodegenerative diseases. Pharmaceuticals (Basel). 2010;3(4):839-915.
3. Crunkhorn S. Neurodegenerative disorders: Restoring the balance. Nat Rev Drug Discov. 2011;10(8):576.
4. Sas K, Robotka H, Toldi J, et al. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. J Neurol Sci. 2007;257(1-2):221-239.
5. Douarre C, Sourbier C, Dalla Rosa I, et al. Mitochondrial topoisomerase I is critical for mitochondrial integrity and cellular energy metabolism. PLoS One. 2012;7(7):e41094.
6. Hollensworth SB, Shen C, Sim JE, et al. Glial cell type-specific responses to menadione-induced oxidative stress. Free Radic Biol Med. 2000;28(8):1161-1174.
7. Chen JQ, Yager JD, Russo J. Regulation of mitochondrial respiratory chain structure and function by estro-gens/estrogen receptors and potential physiologi-cal/pathophysiological implications. Biochim Biophys Acta. 2005;1746(1):1-17.
8. Ghezzi D, Zeviani M. Assembly factors of human mito-chondrial respiratory chain complexes: physiology and pathophysiology. Adv Exp Med Biol. 2012;748:65-106.
9. Shoubridge EA, Wai T. Mitochondrial DNA and the mammalian oocyte. Curr Top Dev Biol. 2007;77:87-111.
10. Porter RK, Brand MD. Mitochondrial proton conductance and H+/O ratio are independent of electron transport rate in isolated hepatocytes. Biochem J. 1995;310(Pt 2):379-382.
11. Zhang Y, Wang M, Li H, et al. Accumulation of nuclear and mitochondrial DNA damage in the frontal cortex cells of patients with HIV-associated neurocognitive disorders. Brain Res. 2012;1458:1-11.
12. Wei YH, Lu CY, Wei CY, et al. Oxidative stress in human aging and mitochondrial disease? consequences of de-fective mitochondrial respiration and impaired antioxidant enzyme system. Chin J Physiol. 2001;44(1):1-11.
13. Selivanov VA, Votyakova TV, Pivtoraiko VN, et al. Reac-tive oxygen species production by forward and reverse electron fluxes in the mitochondrial respiratory chain. PLoS Comput Biol. 2011;7(3):e1001115.
14. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature. 2000;408(6809):239-247.
15. Van Houten B, Woshner V, Santos JH. Role of mitochon-drial DNA in toxic responses to oxidative stress. DNA Repair (Amst). 2006;5(2):145-152.
16. Voets AM, Huigsloot M, Lindsey PJ, et al. Transcriptional changes in OXPHOS complex I deficiency are related to anti-oxidant pathways and could explain the disturbed calcium homeostasis. Biochim Biophys Acta. 2012; 1822(7):1161-1168.
17. Castro Mdel R, Suarez E, Kraiselburd E, et al. Aging in-creases mitochondrial DNA damage and oxidative stress in liver of rhesus monkeys. Exp Gerontol. 2012;47(1): 29-37.
18. Alexeyev MF. Is there more to aging than mitochondrial DNA and reactive oxygen species? FEBS J. 2009; 276(20):5768-5787.
19. Andreazza AC, Shao L, Wang JF, et al. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry. 2010;67(4):360-368.
20. Vajrala V, Claycomb JR, Sanabria H, et al. Effects of os-cillatory electric fields on internal membranes: an analyti-cal model. Biophys J. 2008;94(6):2043-2052.
21. Kirkinezos IG, Bacman SR, Hernandez D, et al. Cytoch-rome c association with the inner mitochondrial mem-brane is impaired in the CNS of G93A-SOD1 mice. J Neurosci. 2005;25(1):164-172.
22. Stewart VC, Heales SJ. Nitric oxide-induced mitochondrial dysfunction implications for neurodegeneration. Free Radic Biol Med. 2003;34(3):287-303.
23. Valko M, Leibfritz D, Moncol J, et al. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007;39(1):44-84.
24. Sultana R, Poon HF, Cai J, et al. Identification of nitrated proteins in Alzheimer's disease brain using a redox pro-teomics approach. Neurobiol Dis. 2006;22(1):76-87.
25. Beal MF. Energetics in the pathogenesis of neurodege-nerative diseases. Trends Neurosci. 2000;23(7):298-304.
26. Fu JD, Yang HT. Developmental regulation of intracellular calcium homeostasis in early cardiac myocytes. Sheng Li Xue Bao. 2006;58(2):95-103.
27. Martín M, Macías M, Escames G, et al. Melatonin-induced increased activity of the respiratory chain complexes I and IV can prevent mitochondrial damage induced by ruthe-nium red in vivo. J Pineal Res. 2000;28(4):242-248.
28. Chang Y, Huang SK, Wang SJ. Coenzyme Q10 inhibits the release of glutamate in rat cerebrocortical nerve ter-minals by suppression of voltage-dependent calcium in-flux and mitogen-activated protein kinase signaling path-way. J Agric Food Chem. 2012;60(48):11909-11918.
29. Martel MA, Soriano FX, Baxter P, et al. Inhibiting pro-death NMDA receptor signaling dependent on the NR2 PDZ ligand may not affect synaptic function or syn-aptic NMDA receptor signaling to gene expression. Channels (Austin). 2009;3(1):12-15.
30. Mattson MP. Calcium and neurodegeneration. Aging Cell. 2007;6(3):337-350.
31. Mattson MP, Magnus T. Ageing and neuronal vulnerability. Nat Rev Neurosci. 2006;7(4):278-294.
32. Toescu EC. Normal brain ageing: models and mechan-isms. Philos Trans R Soc Lond B Biol Sci. 2005; 360(1464):2347-2354.
33. van der Vliet A, Hoen PA, Wong PS, et al. Formation of S-nitrosothiols via direct nucleophilic nitrosation of thiols by peroxynitrite with elimination of hydrogen peroxide. J Biol Chem. 1998;273(46):30255-30262.
34. Joshi G, Sultana R, Perluigi M, et al. In vivo protection of synaptosomes from oxidative stress mediated by Fe2+/H2O2 or 2, 2-azobis-(2-amidinopropane) dihy-drochloride by the glutathione mimetic tricyclodecan-9-yl-xanthogenate. Free Radic Biol Med. 2005;38(8): 1023-1031.
35. Ross WN. Understanding calcium waves and sparks in central neurons. Nat Rev Neurosci. 2012;13(3):157-168.
36. Martin LJ. The mitochondrial permeability transition pore: A molecular target for amyotrophic lateral sclerosis ther-apy. Bio-chim Biophys Acta. 2010;1802(1):186-197.
37. Szeto HH. Mitochondria-targeted peptide antioxidants: novel neuroprotective agents. AAPS J. 2006;8(3): E521-531.
38. Brand MD, Affourtit C, Esteves TC, et al. Mitochondrial superoxide: production, biological effects, and activation of uncoupling proteins. Free Radic Biol Med. 2004;37(6): 755-767.
39. Zeviani M, Simonati A, Bindoff LA. Ataxia in mitochondrial disorders. Handb Clin Neurol. 2012;103:359-372.
40. Haas RH. The evidence basis for coenzyme Q therapy in oxidative phosphorylation disease. Mitochondrion. 2007;7 Suppl:S136-145.
41. Wilson DF, Harrison DK, Vinogradov SA. Oxygen, pH, and mitochondrial oxidative phosphorylation. J Appl Physiol. 2012;113(12):1838-1845.
42. Hansford RG. Physiological role of mitochondrial Ca2+ transport. J Bioenerg Biomembr. 1994;26(5):495-508.
43. Nicholls DG, Budd SL. Mitochondria and neuronal survival. Physiol Rev. 2000;80(1):315-360.
44. Chinnery PF, Elliott HR, Hudson G, et al. Epigenetics, epidemiology and mitochondrial DNA diseases. Int J Ep-idemiol. 2012;41(1):177-187.
45. Schon EA, Manfredi G. Neuronal degeneration and mi-tochondrial dysfunction. J Clin Invest. 2003;111(3): 303-312.
46. Kasote DM, Hegde MV, Katyare SS. Mitochondrial dys-function in psychiatric and neurological diseases: Cause(s), consequence(s), and implications of antioxidant therapy. Biofactors. in press.
47. Wojda U, Salinska E, Kuznicki J. Calcium ions in neuronal degeneration. IUBMB Life. 2008;60(9):575-590.
48. Ferreiro E, Baldeiras I, Ferreira IL, et al. Mitochondrial-and endoplasmic reticulum-associated oxidative stress in Alzheimer's disease: from pathogenesis to biomarkers. Int J Cell Biol. 2012;2012:735206.
49. Anandatheerthavarada HK, Biswas G, Robin MA, et al. Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mito-chondrial function in neuronal cells. J Cell Biol. 2003; 161(1):41-54.
50. Giasson BI, Ischiropoulos H, Lee VM, et al. The relation-ship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases. Free Radic Biol Med. 2002;32(12):1264-1275.
51. Andersen JK. Oxidative stress in neurodegeneration: cause or consequence? Nat Med. 2004;10 Suppl: S18-25.
52. Lustbader JW, Cirilli M, Lin C, et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science. 2004;304(5669):448-452.
53. Dumont M, Ho DJ, Calingasan NY, et al. Mitochondrial dihydrolipoyl succinyltransferase deficiency accelerates amyloid pathology and memory deficit in a transgenic mouse model of amyloid deposition. Free Radic Biol Med. 2009;47(7):1019-1027.
54. Shi Q, Xu H, Yu H, et al. Inactivation and reactivation of the mitochondrial α-ketoglutarate dehydrogenase com-plex. J Biol Chem. 2011;286(20):17640-17648.
55. Coskun PE, Beal MF, Wallace DC. Alzheimer's brains harbor somatic mtDNA control-region mutations that sup-press mitochondrial transcription and replication. Proc Natl Acad Sci U S A. 2004;101(29):10726-10731.
56. Reddy PH. Mitochondrial oxidative damage in aging and Alzheimer's disease: implications for mitochondrially tar-geted antioxidant therapeutics. J Biomed Biotechnol. 2006;2006(3):31372.
57. Tranah GJ, Nalls MA, Katzman SM, et al. Mitochondrial DNA sequence variation associated with dementia and cognitive function in the elderly. J Alzheimers Dis. 2012; 32(2):357-372.
58. Estrada LD, Zanlungo SM, Alvarez AR. C-Abl tyrosine kinase signaling: a new player in AD tau pathology. Curr Alzheimer Res. 2011;8(6):643-651.
59. Cancino GI, Perez de Arce K, Castro PU, et al. c-Abl ty-rosine kinase modulates tau pathology and Cdk5 phos-phorylation in AD transgenic mice. Neurobiol Aging. 2011;32(7):1249-1261.
60. Jing Z, Caltagarone J, Bowser R. Altered subcellular dis-tribution of c-Abl in Alzheimer's disease. J Alzheimers Dis. 2009;17(2):409-422.
61. Zivković L, Spremo-Potparević B, Siedlak SL, et al. DNA damage in Alzheimer disease lymphocytes and its relation to premature centromere division. Neurodegener Dis. in press.
62. López-Erauskin J, Galino J, Bianchi P, et al. Oxidative stress modulates mitochondrial failure and cyclophilin D function in X-linked adrenoleukodystrophy. Brain. 2012; 135(Pt 12):3584-3598.
63. Akhtar MW, Sunico CR, Nakamura T, et al. Redox regula-tion of protein function via cysteine s-nitrosylation and its relevance to neurodegenerative diseases. Int J Cell Biol. 2012;2012:463756.
64. Bemporad F, Chiti F. Protein misfolded oligomers: expe-rimental approaches, mechanism of formation, and structure-toxicity relationships. Chem Biol. 2012;19(3): 315-327.
65. Gonfloni S, Maiani E, Di Bartolomeo C, et al. Oxidative Stress, DNA damage, and c-Abl signaling: at the cros-sroad in neurodegenerative diseases? Int J Cell Biol. 2012;2012:683097.
66. Cho DH, Nakamura T, Fang J, et al. S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury. Science. 2009;324(5923):102-105.
67. Qu J, Nakamura T, Holland EA, et al. S-nitrosylation of Cdk5: potential implications in amyloid-β-related neuro-toxicity in Alzheimer disease. Prion. 2012;6(4):364-370.
68. Nakamura T, Cho DH, Lipton SA. Redox regulation of protein misfolding, mitochondrial dysfunction, synaptic damage, and cell death in neurodegenerative diseases. Exp Neurol. 2012;238(1):12-21.
69. Feeney CJ, Frantseva MV, Carlen PL, et al. Vulnerability of glial cells to hydrogen peroxide in cultured hippocampal slices. Brain Res. 2008;1198:1-15.
70. Giasson BI, Lee VM. A new link between pesticides and Parkinson's disease. Nat Neurosci. 2000;3(12):1227-1228.
71. Lindqvist D, Kaufman E, Brundin L, et al. Non-motor symptoms in patients with Parkinson's disease-correlations with inflammatory cytokines in serum. PLoS One. 2012;7(10):e47387.
72. Abeliovich A. Parkinson's disease: Mitochondrial damage control. Nature. 2010;463(7282):744-745.
73. Matsui H, Gavinio R, Asano T, et al. PINK1 and Parkin complementarily protect dopaminergic neurons in verte-brates. Hum Mol Genet. 2013;22(12):2423-2434.
74. Momb J, Lewandowski JP, Bryant JD, et al. Deletion of Mthfd1l causes embryonic lethality and neural tube and craniofacial defects in mice. Proc Natl Acad Sci U S A. 2013;110(2):549-554.
75. Alleyne T, Mohan N, Adogwa A. Elevated ferric, calcium and magnesium ions in the brain induce protein aggrega-tion in brain mitochondria. West Indian Med J. 2012;61(2): 122-127.
76. Chaturvedi RK, Beal MF. Mitochondria targeted therapeu-tic approaches in Parkinson's and Huntington's diseases. Mol Cell Neurosci. 2013;55:101-114.
77. Puschmann A. Monogenic Parkinson's disease and Par-kinsonism: Clinical phenotypes and frequencies of known mutations. Parkinsonism Relat Disord. 2013; 19(4):407-415.
78. Plaitakis A, Zaganas I, Spanaki C. Deregulation of gluta-mate dehydrogenase in human neurologic disorders. J Neurosci Res. in press.
79. Ciccone S, Maiani E, Bellusci G, et al. Parkinson's Dis-ease: a complex interplay of mitochondrial DNA altera-tions and oxidative stress. Int J Mol Sci. 2013;14(2): 2388-2409.
80. Duplan E, Giaime E, Viotti J, et al. ER-stress-associated functional link between Parkin and DJ-1 via a transcrip-tional cascade involving the tumor suppressor p53 and the spliced X-box binding protein XBP-1. J Cell Sci. 2013; 126(Pt 9):2124-2133.
81. Song S, Jang S, Park J, et al. Characterization of PINK1 (PTEN-induced Putative Kinase 1) mutations associated with Parkinson disease in mammalian cells and Droso-phila. J Biol Chem. 2013;288(8):5660-5672.
82. Lenzi P, Marongiu R, Falleni A, et al. A subcellular analysis of genetic modulation of PINK1 on mitochondrial altera-tions, autophagy and cell death. Arch Ital Biol. 2012;150(2-3):194-217.
83. Cartier AE, Ubhi K, Spencer B, et al. Differential effects of UCHL1 modulation on alpha-synuclein in PD-like models of alpha-synucleinopathy. PLoS One. 2012;7(4):e34713.
84. Shimshek DR, Schweizer T, Schmid P, et al. Excess α-synuclein worsens disease in mice lacking ubiquitin carboxy-terminal hydrolase L1. Sci Rep. 2012;2:262.
85. Hartfield EM, Fernandes HJ, Vowles J, et al. Cellular re-programming: a new approach to modelling Parkinson's disease. Biochem Soc Trans. 2012;40(5):1152-1157.
86. Orenstein SJ, Kuo SH, Tasset I, et al. Interplay of LRRK2 with chaperone-mediated autophagy. Nat Neurosci. 2013; 16(4):394-406.
87. Federoff HJ. Nur (R1) turing a notion on the etiopathoge-nesis of Parkinson's disease. Neurotox Res. 2009;16(3): 261-270.
88. Lin X, Parisiadou L, Sgobio C, et al. Conditional expres-sion of Parkinson's disease-related mutant α-synuclein in the midbrain dopaminergic neurons causes progressive neurodegeneration and degradation of transcription factor nuclear receptor related 1. J Neurosci. 2012;32(27): 9248-9264.
89. Lin CH, Chen ML, Chen GS, et al. Novel variant Pro143Ala in HTRA2 contributes to Parkinson's disease by inducing hyperphosphorylation of HTRA2 protein in mitochondria. Hum Genet. 2011;130(6):817-827.
90. Aasly JO, Shi M, Sossi V, et al. Cerebrospinal fluid amy-loid β and tau in LRRK2 mutation carriers. Neurology. 2012;78(1):55-61.
91. Vandrovcova J, Anaya F, Kay V, et al. Disentangling the role of the tau gene locus in sporadic tauopathies. Curr Alzheimer Res. 2010;7(8):726-734.
92. Coskun P, Wyrembak J, Schriner SE, et al. A mitochon-drial etiology of Alzheimer and Parkinson disease. Bio-chim Biophys Acta. 2012;1820(5):553-564.
93. Obeso JA, Rodriguez-Oroz MC, Goetz CG, et al. Missing pieces in the Parkinson's disease puzzle. Nat Med. 2010;16(6):653-661.
94. Orzi F, Casolla B, Rocchi R, et al. Prion-like mechanisms in epileptogenesis. Neurol Sci. in press.
95. Vila M, Ramonet D, Perier C. Mitochondrial alterations in Parkinson's disease: new clues. J Neurochem. 2008; 107(2):317-328.
96. Horowitz MP, Greenamyre JT. Gene-environment interac-tions in Parkinson's disease: the importance of animal modeling. Clin Pharmacol Ther. 2010;88(4):467-474.
97. Narendra D, Walker JE, Youle R. Mitochondrial quality control mediated by PINK1 and Parkin: links to Parkin-sonism. Cold Spring Harb Perspect Biol. 2012;4(11). pii:a011338.
98. Lee HJ, Patel S, Lee SJ. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neu-rosci. 2005;25(25):6016-6024.
99. Lutz AK, Exner N, Fett ME, et al. Loss of parkin or PINK1 function increases Drp1-dependent mitochondrial frag-mentation. J Biol Chem. 2009;284(34):22938-22951.
100. Narendra D, Tanaka A, Suen DF, et al. Parkin-induced mitophagy in the pathogenesis of Parkinson disease. Au-tophagy. 2009;5(5):706-708.
101. Varçin M, Bentea E, Michotte Y, et al. Oxidative stress in genetic mouse models of Parkinson's disease. Oxid Med Cell Longev. 2012;2012:624925.
102. Manfredi G, Xu Z. Mitochondrial dysfunction and its role in motor neuron degeneration in ALS. Mitochondrion. 2005;5(2):77-87.
103. Cacciatore I, Baldassarre L, Fornasari E, et al. Recent advances in the treatment of neurodegenerative diseases based on GSH delivery systems. Oxid Med Cell Longev. 2012;2012:240146.
104. Kumar H, Lim HW, More SV, et al. The role of free radicals in the aging brain and Parkinson's disease: convergence and parallelism. Int J Mol Sci. 2012;13(8):10478-10504.
105. Lin TK, Cheng CH, Chen SD, et al. Mitochondrial dys-function and oxidative stress promote apoptotic cell death in the striatum via cytochrome c/caspase-3 signaling cascade following chronic rotenone intoxication in rats. Int J Mol Sci. 2012;13(7):8722-8739.
106. Schapira, AH. Mitochondria in the aetiology and patho-genesis of Parkinson's disease. Lancet Neurol. 2008;7(1): 97-109.
107. Rosen DR. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;364(6435):362.
108. Ferri A, Cozzolino M, Crosio C, et al. Familial ALS-superoxide dismutases associate with mitochondria and shift their redox potentials. Proc Natl Acad Sci U S A. 2006; 103(37):13860-13865.
109. Sasaki S, Iwata M. Mitochondrial alterations in the spinal cord of patients with sporadic amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 2007;66(1):10-16.
110. Sasaki S, Warita H, Murakami T, et al. Ultrastructural study of aggregates in the spinal cord of transgenic mice with a G93A mutant SOD1 gene. Acta Neuropathol. 2005;109(3):247-255.
111. Israelson A, Arbel N, Da Cruz S, et al. Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS. Neuron. 2010;67(4):575-587.
112. Magrané J, Manfredi G. Mitochondrial function, morphol-ogy, and axonal transport in amyotrophic lateral sclerosis. Antioxid Redox Signal. 2009;11(7):1615-1626.
113. Kawamata H, Manfredi G. Mitochondrial dysfunction and intracellular calcium dysregulation in ALS. Mech Ageing Dev. 2010;131(7-8):517-526.
114. Corti S, Donadoni C, Ronchi D, et al. Amyotrophic lateral sclerosis linked to a novel SOD1 mutation with muscle mitochondrial dysfunction. J Neurol Sci. 2009;276(1-2): 170-174.
115. Menzies FM, Ince PG, Shaw PJ. Mitochondrial involve-ment in amyotrophic lateral sclerosis. Neurochem Int. 2002;40(6):543-551.
116. Sasaki S, Horie Y, Iwata M. Mitochondrial alterations in dorsal root ganglion cells in sporadic amyotrophic lateral sclerosis. Acta Neuropathol. 2007;114 (6):633-639.
117. Reddy PH, Beal MF. Are mitochondria critical in the pa-thogenesis of Alzheimer's disease? Brain Res Brain Res Rev. 2005;49(3):618-632.
118. Helguera P, Seiglie J, Rodriguez J, et al. Adaptive down-regulation of mitochondrial function in down syn-drome. Cell Metab. 2013;17(1):132-140.
119. Siddiqui A, Rivera-Sánchez S, Castro Mdel R, et al. Mi-tochondrial DNA damage is associated with reduced mi-tochondrial bioenergetics in Huntington's disease. Free Radic Biol Med. 2012;53(7):1478-1488.
120. Marobbio CM, Pisano I, Porcelli V, et al. Rapamycin re-duces oxidative stress in frataxin-deficient yeast cells. Mitochondrion. 2012;12(1):156-161.
121. Xia H, Cao Y, Dai X, et al. Novel frataxin isoforms may contribute to the pathological mechanism of friedreich ataxia. PLoS One. 2012;7(10):e47847.
122. Santos R, Lefevre S, Sliwa D, et al. Friedreich ataxia: molecular mechanisms, redox considerations, and thera-peutic opportunities. Antioxid Redox Signal. 2010;13(5): 651-690.
123. Cooper JM, Korlipara LV, Hart PE, et al. Coenzyme Q10 and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. Eur J Neurol. 2008;15(12):1371-1379.
124. Murphy MP. Targeting lipophilic cations to mitochondria. Biochim Biophys Acta. 2008;1777(7-8):1028-1031.
125. Moreira PI, Zhu X, Wang X, et al. Mitochondria: a thera-peutic target in neurodegeneration. Biochim Biophys Acta. 2010;1802(1):212-220.
126. Herrero MT, Pagonabarraga J, Linazasoro G. Neuropro-tective role of dopamine agonists: evidence from animal models and clinical studies. Neurologist. 2011;17(6 Suppl 1):S54-66.